U.S. Metals and Mining Stock News

NYSE:GPI
NYSE:GPISpecialty Retail

The Bull Case For Group 1 Automotive (GPI) Could Change Following Divergent Analyst Takes On Earnings

In recent days, Group 1 Automotive has faced mixed analyst opinions following fourth-quarter 2025 earnings that fell short of forecasts amid tougher macroeconomic conditions, while executives also received updated incentive terms enhancing protections around potential corporate changes. At the same time, contrasting analyst views, including renewed positive coverage citing the company’s balance sheet strength and resilient underlying operations, highlight how differently investors are...
NasdaqGS:NBIS
NasdaqGS:NBISSoftware

Nebius Group (NBIS) Is Down 8.8% After Missouri OKs 1.2 GW AI Factory Plan – Has The Bull Case Changed?

Nebius Group has received approval from the Independence City Council in Missouri to proceed with construction of its largest U.S. AI factory, a 1.2 GW, 400-acre campus that will deliver more than US$650.00 million in Payments in Lieu of Taxes over 20 years and create around 1,200 construction jobs plus 130 permanent high-tech roles. The project’s closed-loop cooling system, purpose-built connection to the municipal utility, and community benefits plan around STEM and AI education highlight...
NYSE:TK
NYSE:TKOil and Gas

Is It Time To Reassess Teekay (TK) After Its 114% One Year Share Price Surge

If you are wondering whether Teekay's current share price reflects its true value, you are not alone. This article walks through what the numbers actually say about the stock. Teekay's share price recently closed at US$12.29, with returns of 18.1% over 30 days, 39.3% year to date, and 113.7% over the past year, although the last 7 days showed a 4.7% decline. Recent coverage of Teekay has focused on its role in the energy shipping space and how investors are weighing that against broader...
NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

A Look At Summit Therapeutics (SMMT) Valuation As Ivonescimab Advances Through Late Stage Trials And FDA Review

Summit Therapeutics (SMMT) is back in focus after 2025 results showed a net loss of US$1,079.59 million and a fresh US$102.016 million shelf registration, while its lead drug ivonescimab moves through Phase III trials. See our latest analysis for Summit Therapeutics. Despite the widened 2025 loss and the new shelf registration, Summit Therapeutics' recent stock momentum has cooled, with a 7 day share price return of a 5.44% decline and a year to date share price return of a 14.73% decline...
NYSE:EFC
NYSE:EFCMortgage REITs

Assessing Ellington Financial (EFC) Valuation After Recent Share Price Softness And Long Term Returns

Ellington Financial (EFC) has been drawing attention after recent share price moves, with the stock around $12.20 and returns near flat over the past year but weaker over the past 3 months. See our latest analysis for Ellington Financial. Recent trading has been softer, with a 30 day share price return of a 3.17% decline and a 90 day share price return of an 11.08% decline. In contrast, the 1 year total shareholder return of 1.94% and 3 year total shareholder return of 49.65% point to a much...
NYSE:WK
NYSE:WKSoftware

Workiva (WK) Valuation Check After Earnings Beat And Strong Recurring Revenue Momentum

Workiva (WK) is back in focus after a strong quarter in which revenue, billings, and guidance all topped expectations, alongside solid annual recurring revenue and margin trends that have helped support more positive investor sentiment. See our latest analysis for Workiva. Despite the strong quarter, Workiva’s recent share price performance has been mixed, with a 1-day share price return of 4.19% and a 7-day share price return of 4.43% contrasting with a 90-day share price return decline of...
NasdaqGS:SABR
NasdaqGS:SABRHospitality

Sabre (SABR) Is Up 50.0% After Launching AI-First Mosaic Platform And Governance Deal - Has The Bull Case Changed?

In recent days, Sabre Corporation completed a multi-year rebuild of its core systems and unveiled Sabre Mosaic, an AI-first, cloud-based travel technology platform powered by Google Gemini and underpinned by a unified data architecture exceeding 50 petabytes. At the same time, Sabre reached a governance agreement with major shareholder Constellation Software, adding Vela Software Group CEO Damian McKay to its board and ending a period of takeover-related tension. Next, we’ll examine how...
NasdaqGS:ECPG
NasdaqGS:ECPGConsumer Finance

Encore Capital Record Quarter Highlights Debt Purchases Digital Shift And Valuation

Encore Capital Group (NasdaqGS:ECPG) reported record portfolio purchases and collections in its latest quarterly results. Management linked the performance to operational improvements and expanded digital capabilities in the U.S. business. The fourth quarter showed material outperformance for the company compared with its recent performance. Encore Capital Group focuses on purchasing and collecting consumer debt portfolios, with a large presence in the U.S. market. The latest update...
NasdaqGM:SOUN
NasdaqGM:SOUNSoftware

SoundHound AI (SOUN) Valuation Check As Revenue Growth And 2026 Guidance Draw Fresh Interest

SoundHound AI (SOUN) is back in focus after reporting strong year over year revenue growth, issuing upbeat 2026 guidance, and rolling out its new Sales Assist AI agent for retail customers. See our latest analysis for SoundHound AI. The recent earnings beat, upbeat 2026 revenue outlook and new product launches have not prevented some volatility. The 90 day share price return shows a decline of 35.19%, while the 3 year total shareholder return of about 2.7x points to strong longer term...
NasdaqGS:BTSG
NasdaqGS:BTSGHealthcare

Is BrightSpring Health Services (BTSG) Pricing Make Sense After 142% One Year Surge

If you are wondering whether BrightSpring Health Services is priced attractively or already reflects a lot of optimism, you are not alone in asking whether the current share price lines up with its fundamentals. The stock recently closed at US$41.77, and its returns sit at 4.1% over 7 days, 7.0% over 30 days, 8.8% year to date, and 142.4% over 1 year. This naturally raises questions about how much of the story is already in the price. Recent news coverage has focused on BrightSpring Health...
NYSE:A
NYSE:ALife Sciences

Agilent Technologies (A) Valuation Check After Higher 2026 Revenue Guidance And Q2 Outlook

Agilent Technologies (A) drew fresh investor attention after raising its full year 2026 revenue guidance to US$7.3b to US$7.5b and issuing second quarter revenue guidance of US$1.79b to US$1.82b. See our latest analysis for Agilent Technologies. Even with the raised guidance and first quarter revenue of US$1.80b, the stock’s recent momentum has been weak. The 30 day share price return was 10.62%, while the 1 year total shareholder return showed a 5.92% decline, which suggests that investors...
NYSE:MHK
NYSE:MHKConsumer Durables

A Look At Mohawk Industries (MHK) Valuation After S&P 500 Inclusion And Luxury Vinyl Tile Leadership

Mohawk Industries (MHK) has just been added to the S&P 500 Index. A recent 2025 Luxury Vinyl Tiles report also ranks the company among quadrant leaders, putting its flooring business model firmly in the spotlight. See our latest analysis for Mohawk Industries. Despite the S&P 500 inclusion and recognition in the Luxury Vinyl Tiles report, Mohawk’s recent trading has been weak. A 7 day share price return of 12.86% and a 1 year total shareholder return of 8.01% point to fading short term...
NYSE:HCA
NYSE:HCAHealthcare

HCA’s AI Push and ACA EBITDA Hit Might Change The Case For Investing In HCA Healthcare (HCA)

In late February 2026, HCA Healthcare outlined AI, network expansion, and workforce initiatives at major investor and industry conferences, while also flagging an anticipated US$600.00 million to US$900.00 million EBITDA impact in 2026 from Affordable Care Act reforms and confirming an upcoming board retirement. These updates, alongside fresh analyst endorsements and continued facility expansion in Florida, highlight how HCA is balancing growth investments with emerging regulatory and...
NYSE:CPA
NYSE:CPAAirlines

Is Copa Holdings (CPA) Fairly Priced After Recent Share Price Pullback?

If you are wondering whether Copa Holdings is still sensibly priced after its recent run, this article walks through what the current share price could mean for you as an investor. The stock closed at US$126.90, with a 14.3% decline over the past 7 days and a 12.9% decline over 30 days, set against returns of 4.2% year to date, 38.7% over 1 year, 60.3% over 3 years, and 65.8% over 5 years. Recent headlines around Copa often focus on its role in Latin American air travel and its position...
NasdaqGS:DOCU
NasdaqGS:DOCUSoftware

Is DocuSign (DOCU) Pricing Looked At Differently After Its Recent Share Price Rebound?

If you are wondering whether DocuSign is a bargain or a value trap at around US$48.23, you are not alone. Many investors are trying to work out what a fair price looks like today. Over the past week the share price is up 5.5% and it is 4.7% higher over the last 30 days. Yet year to date the stock is down 25.6% and it has returned negative 39.5% over 1 year and negative 78.6% over 5 years. These mixed returns have kept DocuSign on a lot of watchlists, as some investors reassess their view of...
NYSE:MOD
NYSE:MODBuilding

Modine Earnings Beat Highlights Data Center Push And Spin Off Plan

Modine Manufacturing (NYSE:MOD) reported Q3 FY2026 results that were ahead of its own expectations. The company raised its full year FY2026 guidance following the quarter. Management highlighted strong growth in Modine's data center related business. Modine announced plans to spin off its Performance Technologies segment into a separate company. Modine Manufacturing focuses on thermal management and engineered solutions across transportation, industrial, and building markets, with data...
NYSE:WEC
NYSE:WECIntegrated Utilities

Is WEC Energy Group’s (WEC) New Connectivity Push Quietly Reshaping Its Grid Modernization Strategy?

On 2 March 2026, OneLayer announced that WEC Energy Group is using its OneLayer Bridge platform to manage and monitor cellular-connected field devices across multiple carrier networks, aiming to improve service resiliency and reduce operational complexity in WEC’s distributed electric and natural gas operations. This deployment underscores how WEC is tying advanced connectivity tools directly into its broader grid modernization and infrastructure investments to support reliable, long-term...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Assessing Grab Holdings (NasdaqGS:GRAB) Valuation After Prolonged Share Price Weakness

What recent returns tell you about Grab Holdings (GRAB) Grab Holdings (NasdaqGS:GRAB) has been under pressure recently, with the stock showing negative returns over the past week, month and past 3 months, and a negative 1 year total return. Over a longer horizon, the 3 year total return is positive, while the 5 year figure is negative, highlighting how timing has influenced outcomes for investors who bought at different points. See our latest analysis for Grab Holdings. Grab Holdings’ share...
NasdaqGS:CAR
NasdaqGS:CARTransportation

Avis Smoke Free Fleet Policy And What It Could Mean For CAR Stock

Avis Budget Group (NasdaqGS:CAR) has imposed a company wide ban on smoking in all North American rental vehicles. The new policy introduces significant penalties for customers who violate the smoke free rules. Avis is the first major rental car company to roll out a blanket smoke free fleet policy at this scale. Health advocacy groups are publicly supporting the move, highlighting its focus on cleaner and healthier vehicles. Avis Budget Group, the parent of Avis and Budget, operates a large...
NYSE:NIO
NYSE:NIOAuto

Assessing NIO (NYSE:NIO) Valuation After Recent Share Price Swings And Mixed Return Profile

Why NIO (NYSE:NIO) is on investors' radar NIO (NYSE:NIO) has drawn fresh attention after recent trading left the shares at US$4.72, with mixed return figures across the past week, month, past 3 months, year to date, and over the past year. See our latest analysis for NIO. At around US$4.72, NIO’s recent weakness, including a 7 day share price return of 7.27% and a 90 day share price return of 6.35%, contrasts with an 11.32% 1 year total shareholder return. This hints at fading short term...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte’s Cash Flow Gains Reshape Earnings Outlook And Capital Return Options

Incyte, ticker NasdaqGS:INCY, is reporting sustained revenue growth alongside an expansion in free cash flow margins. The company is also showing strong earnings momentum, pointing to robust operational performance. These trends highlight an improved ability to invest in the business or return value to shareholders through capital allocation choices. For investors tracking NasdaqGS:INCY, the latest numbers focus attention on how the business is running, not just where the share price sits...
NYSE:CCS
NYSE:CCSConsumer Durables

Century Communities Expands Buyer Reach With New Spartanburg And Brighton Projects

Century Communities (NYSE:CCS) announced new Ellison Townhomes in Spartanburg, offering low maintenance living with modern amenities. The company also introduced Bella Vista near Brighton and Denver, featuring updated floorplans and integrated smart home technology. These launches expand Century Communities' regional footprint and product mix outside of its regular earnings and guidance updates. For you as an investor, this news sits at the core of what Century Communities does: developing...
NYSE:ZTS
NYSE:ZTSPharmaceuticals

A Look At Zoetis (ZTS) Valuation After Recent Share Price Weakness

How Zoetis stock has been performing Zoetis (ZTS) has been trading under some pressure recently, with the share price seeing a 3% decline over the past day and a 5.8% decline over the past week. Over a longer stretch, the stock has been comparatively steadier, with a marginal decline over the past month and a 3% total return gain over the past 3 months. The 1 year and multi year returns remain negative. See our latest analysis for Zoetis. At a share price of $122.23, Zoetis has seen short...
NasdaqGM:WVE
NasdaqGM:WVEPharmaceuticals

Wave Life Sciences (WVE) Valuation Check After New RNA Editing And Obesity Trial Updates

Wave Life Sciences (WVE) has drawn fresh attention after announcing a late breaking oral presentation of WVE-006 clinical data and reporting continued progress for its obesity candidate WVE-007, including plans for new trials. See our latest analysis for Wave Life Sciences. Despite the recent clinical news, the 1 day share price return of Wave Life Sciences is down 3.72% and the 7 day share price return is down 14.06%. However, the 90 day share price return of 76.23% and 1 year total...